Trial Profile

A Phase 3, Randomized, Double-blind Clinical Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-line Treatment in Participants With HER2 Negative, Previously Untreated, Unresectable or Metastatic Gastric Orgastroesophageal Junction Adenocarcinoma (KEYNOTE-859)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Capecitabine; Cisplatin; Fluorouracil; Oxaliplatin
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Registrational; Therapeutic Use
Acronyms KEYNOTE-859; MK-3475-859/KEYNOTE-859
Sponsors Merck Sharp & Dohme Corp.

13 May 2025 According to a Merck Sharp & Dohme media release, data from this study will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (May 30-June 3).
18 Mar 2025 Status changed from active, no longer recruiting to completed.
17 Jan 2025 Planned End Date changed from 1 Mar 2025 to 3 Mar 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com